areas other than Panama, and for A. palmata are also needed. Identifying disease resistant 48 phenotypes is the first step to leveraging them to enhance resilience of restored populations and 49 to understanding their underlying biological mechanisms.
50
The protocol for challenge experiments described in this document is intended to be 51 implemented in a standardized way, with the goal of providing comparable information 52 regarding relative disease resistance/susceptibility among cultured genotypes from different 53 nurseries and regions. One factor that is particularly difficult to standardize is the identity or 54 etiology of the inoculants used in the challenge experiments, given poor characterization of 55 disease etiology in these species. This uncertainty must be acknowledged and standardized to 56 the degree possible in terms of observable signs and in taking care to randomize the pairing of 57 inoculants with test genets. However, it should be remembered that the goal of this protocol is to 58 test the susceptibility of coral stocks to disease, not to test or describe the process or mechanisms conducted to obtain a robust sample size for this parameter. we recommend prioritizing effort and coral material to challenge assays, rather than controls.
236
There is inherent variability in the implementation of field challenge assays, especially as 237 the lack of diagnostic tests for Atlantic reproductive effort? thermal tolerance?) or molecular studies to discern mechanistic differences.
264
Table 1: Example challenge assay results from two trials testing four Acropora cervicornis genets.
265
TRIAL 1 TRIAL 2 POOLED Figure 1 Step 1: Test fragments of both species recently staged prior to conducting challenge assays. In 288 this case, replicate fragments of each genotype (designated by the white numbered goat tag) are staged on 289 the same tree branch. Fragments should heal/stabilize for at least two weeks prior to initiating assays. assays, a small degree of abrasion is visible after 7 days exposure, but no signs of progressive tissue 318 loss/disease are evident 319 320
